umifenovir
Trade name: Arbidol
Small moleculeexperimentalCOVID-19
Umifenovir, sold under the brand name Arbidol, is sold and used as an antiviral medication for influenza in Russia and China. The drug is manufactured by Pharmstandard. It is not approved by the U.S. Food and Drug Administration (FDA) for the treatment or prevention of influenza. — Wikipedia
Clinical trial activity
11 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
7
Earliest trial started Sep 1, 2011 (NCT01651663)
Timeline
Indications
Approved for
Mechanism of action
- Influenza virusINHIBITOR
Influenza virus inhibitor
- HemagglutininNEGATIVE MODULATOR
Hemagglutinin negative modulator
Binds and stabilises viral hemagglutin preventing rearrangements required for membrane fusion and entry into the host cell.
Broad-spectrum antiviral
Hydrophobic cavity in the HA trimer stem at the interface between two protomers.
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12- Mol. weight
- 477.42 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaUmifenovir ↗
- ChEMBLCHEMBL1214598 ↗
Also known as
- 1-methyl-2-((phenylthio)methyl)-3-carbethoxy-4-((dimethylamino)methyl)-5-hydroxy-6-bromindole hydrochloride
- arbidol
- arbidol
- arbidol
- arbidol
- arbidol
- arbidole
- arbidole
- arbidole
- arbidole
- arbidole
- umifenovir
- umifenovir
- umifenovir
- umifenovir
- umifenovir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06462417 | N/A | Jun 20, 2024 | Huazhong University of Science and Technology, National Natural Science Foundation of China |
| NCT04476719 | Phase 1 | Jul 9, 2020 | Farmagen Ar-Ge Biyot. Ltd. Sti, Novagenix Bioanalytical Drug R&D Center, RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. |
| NCT04350684 | Phase 4 | Apr 15, 2020 | Shahid Beheshti University of Medical Sciences |
| NCT04273763 | N/A | Feb 16, 2020 | WanBangDe Pharmaceutical Group Co.,Ltd., Wenzhou Medical University |
| NCT04260594 | Phase 4 | Feb 7, 2020 | Jiao Tong University |
| NCT04255017 | Phase 4 | Feb 1, 2020 | Huazhong University of Science and Technology |
| NCT04254874 | Phase 4 | Feb 1, 2020 | Huazhong University of Science and Technology |
| NCT04252885 | Phase 4 | Jan 28, 2020 | Guangzhou Medical University |
| NCT03851991 | Phase 4 | Apr 5, 2019 | Shengjing Hospital |
| NCT03787459 | Phase 3 | Jan 18, 2019 | Capital Medical University, Government of China, Peking University, University of Oxford |
| NCT01651663 | Phase 4 | Sep 1, 2011 | Pharmstandard |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 3 | 3 | 2 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Farmagen Ar-Ge Biyot. Ltd. Sti | For profit | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2019 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Natural Science Foundation of China | Government | 1 | 0 | 1 | 2024 |
| Novagenix Bioanalytical Drug R&D Center | For profit | 1 | 0 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Pharmstandard | For profit | 1 | 1 | 1 | 2011 |
| RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | For profit | 1 | 1 | 1 | 2020 |
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Shengjing Hospital | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2019 |
| WanBangDe Pharmaceutical Group Co.,Ltd. | For profit | 1 | 0 | 1 | 2020 |
| Wenzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
16 organizations
Page 1 / 1